+

EP3869965A1 - Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien - Google Patents

Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien

Info

Publication number
EP3869965A1
EP3869965A1 EP19790230.7A EP19790230A EP3869965A1 EP 3869965 A1 EP3869965 A1 EP 3869965A1 EP 19790230 A EP19790230 A EP 19790230A EP 3869965 A1 EP3869965 A1 EP 3869965A1
Authority
EP
European Patent Office
Prior art keywords
znmo0
composite material
miti
triclinic
composite
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP19790230.7A
Other languages
German (de)
English (en)
Inventor
J. Peter Guggenbichler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amistec & Co KG GmbH
Original Assignee
Amistec & Co KG GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amistec & Co KG GmbH filed Critical Amistec & Co KG GmbH
Publication of EP3869965A1 publication Critical patent/EP3869965A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
    • A01N59/16—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/08—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing solids as carriers or diluents
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
    • A01N25/12—Powders or granules

Definitions

  • Zinc molybdate with triclinic crystal structure as an antimicrobial agent
  • the invention relates to the use of a triclinic form of zinc molybdate (ZnMo0 4 ) as an antimicrobial active ingredient, composite materials which comprise such zinc molybdate and processes for their production.
  • metals and metal compounds are used. Because of their good antimicrobial properties, silver and copper in particular are often used.
  • the elemental metal is provided in a form with the largest possible surface area in order to achieve high activity. Nanoparticles, foamed metal or nanoparticles fixed on a carrier are particularly suitable here.
  • a second variant provides for the provision of soluble metal salts, which are incorporated, for example, in zeolites or directly in a composite material.
  • the noble metals or noble metal ions mentioned are comparatively expensive and, moreover, are almost completely inactivated by sulfur-containing compounds or high electrolyte concentrations.
  • molybdate and tungstate as antimicrobial agents has also recently been discussed. These compounds are comparatively inexpensive and also non-toxic since they are practically insoluble in water. However, the antimicrobial effectiveness of the molybdates and tungstates examined so far is often not sufficient.
  • the object of the present invention is therefore to provide an anti-microbial active ingredient with improved activity and a cost-effective possibility for the effective protection of materials and surfaces against the settlement of microorganisms.
  • Zinc molybdate the antimicrobial effect of which has already been described in the field, is usually in a tetragonal crystal structure. It is insoluble in water and therefore practically non-toxic.
  • zinc molybdate in addition to the known tetragonal crystal structure, can also be stable in a triclinic crystal structure and in this form shows a significantly higher antimicrobial activity than in other crystal forms. The effect is significantly improved compared to that of tetragonal zinc molybdate with the same grain size.
  • Triclinic zinc molybdate can be obtained by ultrasonically assisted reaction of a solution of one or more water-soluble molybdates with a solution of one or more water-soluble zinc (II) salts.
  • the water-insoluble zinc molybdate formed in the reaction of the educt salts precipitates in the form of triclinic crystals.
  • the grain size of the triclinic crystals can vary.
  • a particularly good antimicrobial activity has been found according to the invention for zinc molybdate in the form of particles with a triclinic crystal structure and one average grain size in the range from 0.10 miti to 5.0 miti, preferably between 0.25 miti and 5.0 miti.
  • a first aspect of the invention therefore relates to the use of zinc molybdate as an antimicrobial active ingredient, ZnMo0 4 in the form of particles with a triclinic crystal structure and an average grain size between 0.1 miti and 5.0 miti, preferably 0.25 miti and 5.0 miti is present.
  • Triklines zinc molybdate is not toxic to humans and animals and therefore has excellent biocompatibility. It can be produced comparatively inexpensively and shows a strong antimicrobial effect even in small quantities. In addition, zinc molybdate is not inactivated by sulfur-containing compounds or by a high electrolyte concentration, but retains its effectiveness.
  • Zinc molybdate with a triclinic crystal structure and the grain size given above shows a high antimicrobial activity against a broad spectrum of microorganisms, including algae, fungi and viruses, as well as gram-positive and gram-negative microorganisms regardless of their antibiotic resistance.
  • microorganisms against which triclinic zinc molybdate according to the invention is active include Lactobacillus acidophilus, Pseudomonas, for example P. aeruginosa, Salmonella, for example S aureus, E. coli, Candida Spp, C. albicans, C. glabrata and C.
  • the zinc molybdate according to the invention is particularly effective against algae growth.
  • the grain size of ZnMo0 4 is preferably in the range from 0.10-2.5 mm, more preferably in the range from 0.15-2.5 m, and more preferably in the range from 0.2 mm to less than 1, 0 miti. Particles smaller than 0.10 miti and in particular nanoparticles are not provided according to the invention.
  • Zinc molybdate with a triclinic crystal structure is particularly effective in the submicron range.
  • Triclinic zinc molybdate itself is water-insoluble. When in contact with water or air humidity, zinc molybdate lowers the pH. The zinc molybdate itself does not go into solution and is not broken down or washed out of a material.
  • triclinic zinc molybdate can be used alone or in combination with other active substances and / or auxiliary substances.
  • triclinic zinc molybdate is combined with molybdenum oxide Mo0 3 , since this can further improve the antimicrobial effectiveness.
  • M0O3 can exist in any crystal structure, for example orthorhombic or monoclinic. M0O3 with an orthorhomic crystal structure has proven to be particularly advantageous according to the invention.
  • Triklines ZnMo0 4 and M0O3 can be in the form of a mixture of crystals or as mixed crystals. The use of a mixture or mixed crystal of triclinic ZnMo0 4 and orthorhombic M0O3 is particularly preferred.
  • triclinic zinc molybdate can be incorporated into a material which is to be provided with antimicrobial properties, or at least deposited on its surface. This results in an antimicrobial composite.
  • Another object of the invention is accordingly an antimicrobial composite material comprising ZnMo0 4 in the form of particles with a triclinic crystal structure and an average grain size between 0.1 pm and 5.0 miti, more preferably between 0.20 pm and 5.0 miti, stronger preferably between 0.25 pm and 5.0 pm, more preferably in the range from 0.50 pm and 2.5 pm and again more preferably in the range from 0.70 pm to 1.5 pm.
  • a composite material is understood to mean a material which consists of two or more materials bonded to one another, at least one of the materials being the triclinic zinc molybdate as defined above.
  • the further material can in principle be made of any material and, for example, can itself be a composite material.
  • triclinic zinc molybdate gives an inventive composite material an antimicrobial effect.
  • the adherence of pathogenic germs is greatly reduced.
  • the proliferation of microorganisms and the formation of biofilms are inhibited. This is particularly important, for example, in hospitals, nursing homes, etc., since microorganisms in biofilms from antibiotics, organic biocides, disinfectants and the like do not or at least do not are permanently removable. Since a lowering of the pH value is only required in the area of the surface boundary layer of the composite material, or a component or product made from it, correspondingly small amounts of zinc molybdate in the area of the surface are sufficient to achieve the desired antimicrobial effectiveness.
  • the adherence of algae and / or biofilms to surfaces is reduced. Accordingly, the use of the zinc molybdate of the invention to prevent fouling, i.e. the undesired settlement of organisms on technical surfaces, e.g. Hulls, a preferred embodiment of the invention.
  • Triclinic zinc molybdate is essentially not water-soluble, so it does not wash out of the composite, but stays there and its antimicrobial effectiveness is maintained over the entire life of the composite.
  • triclinic zinc molybdate is retained even better in the material than zinc molybdate with a different crystal structure.
  • the at least one further material of the composite material can in principle be selected from any material classes.
  • it can be an inorganic, metallic, ceramic or organic material or any combination thereof.
  • further materials are, for example, plastics, paints, lacquers, silicones, rubber, rubber, melamine, acrylates, methyl acrylates, waxes, epoxy resins, glass, metal, ceramics and others.
  • the composite material according to the invention comprises at least one organic polymer, or a compound and / or a silicone, as a further material.
  • the material in or on which for the purpose of antimicrobial equipment the triclinic zinc molybdate is introduced can form a solid and / or liquid matrix. It can be provided that triclinic zinc molybdate is added in such a way that it makes up between 0.1% and 10% (percentages by weight or volume) of the total weight or total volume.
  • the composite material can in principle be designed as a layer composite, fiber composite, particle composite or penetration composite.
  • the composite material according to the invention can be solid or liquid under standard conditions.
  • the composite material can be in the form of a solution, suspension and / or dispersion, for example as a lacquer or liquid coating agent.
  • Varnishes or coating compositions according to the invention can be applied to any suitable surface such as plastics, metals, wood, stone and other building materials. In such a case, the composite material is hardened after hardening.
  • Triclinic zinc molybdate can be arranged on the surface of the composite and / or distributed in the composite.
  • An arrangement of triclinic zinc molybdate in the region of the surface of the composite material is preferred according to the invention, since an antimicrobial effect is desired here.
  • zinc molybdate can be applied as a layer or part of a layer to a substrate or carrier material. Basically, only one or more areas of the surface or the entire surface of the composite material can be given antimicrobial properties by triclinic zinc molybdate.
  • triclinic zinc molybdate can also be arranged within the composite material or distributed in the composite material. This ensures that the antimicrobial effect is permanently retained even if the composite material wears out on the surface.
  • the composite material in the context of the present invention can in principle be present as a semifinished product, ie as a semifinished material, which only reaches its final form of use after further processing steps.
  • the composite material can already be designed as a finished component, which can be used for its intended purpose without further processing steps.
  • a composite material according to the invention can contain triclinic zinc molybdate alone or in combination with other active substances and / or auxiliary substances.
  • triclinic zinc molybdate is combined with molybdenum oxide Mo0 3 , since this can further improve the antimicrobial effectiveness.
  • M0O3 can exist in any crystal structure, for example orthorhombic or monoclinic.
  • Triklines ZnMo0 4 and M0O3 can be in the form of a mixture of crystals or as mixed crystals.
  • the use of a mixture or mixed crystal of triclinic ZnMo0 4 and orthorhombic M0O3 is particularly preferred.
  • a composite material according to the invention has, in addition to triclinic ZnMo0 4 and possibly M0O3, no additional antimicrobial compounds, such as silver or silver compounds, in particular nanosilver or soluble silver compounds such as silver nitrate or the like. Copper, organic biocides, zeolites and the like are preferably also not contained in a composite material according to the invention. In this way, better environmental compatibility and a significant reduction in costs are achieved.
  • the mass content of triclinic zinc molybdate based on the total mass of the composite material is advantageously between 0.1 and 80% by weight, in particular between 1.5 and 30% by weight and preferably between 1.8 and 5.0% by weight. This mass ratio ensures a particularly high antimicrobial activity with the least possible use of zinc molybdate.
  • triclinic zinc molybdate is used in combination with at least one hydrophilizing or hygroscopic agent which is arranged at least in the area of the surface of the composite material.
  • hydrophilizing or hygroscopic agent which is arranged at least in the area of the surface of the composite material.
  • suitable hydrophilizing and / or hygroscopic agents are in particular SiO 2 , in particular in the form of silica gel or as pyrogenic silicon dioxide.
  • Si0 2 is preferably with a Particle size distribution in the range between 0.25 miti and 25 miti mean particle diameter used.
  • hydrophilizing and / or hygroscopic agents which can be used according to the invention are organic acids, such as abietic acid, arachidonic acid, arachic acid, behenic acid, capric acid, caproic acid, cerotic acid, erucic acid, fusaric acid, fumaric acid, bile acids, icosenoic acid, isophthalic acid, lactonic acid, lauric acid, lauric acid, lauric acid Linolenic acid, levopimaric acid, linoleic acid, margaric acid, melissic acid, montanic acid, myristic acid, neoabietic acid, nervonic acid, nonadecanoic acid, oleic acid, palmitic acid, palmitoleic acid, pelargonic acid (nonanoic acid), pimaric acid, palustric acid, palmitic acid, ricinoleic acid, undecanoic acid, stearic acid,
  • organic acids
  • malonic acid maleic acid and maleic anhydride
  • lactic acid acetic acid
  • citric acid citric acid
  • salicylic acid and ascorbic acid
  • Acid anhydrides ampholytic substances, buffer systems, polymer acids, ion exchange resins, and also acid sulfonates and acid halides can also be used.
  • the mass content of hydrophilizing and / or hygroscopic agent based on the total weight of the composite material is advantageously in the range of 0.1% and 15%.
  • the mass content can be 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13% or 14% be.
  • the mass content or the mass ratio of the hydrophilizing and / or hygroscopic agent can be adjusted such that it corresponds to the selected mass content of triclinic zinc molybdate.
  • triclinic zinc molybdate is at least partially coated and / or agglomerated with the hydrophilizing and / or hygroscopic agent, in particular SiO 2 . This ensures a spatial proximity of the two classes of compounds in a simple manner, so that zinc molybdate is supplied directly with the moisture required for lowering the pH value even under particularly dry conditions.
  • an antimicrobially active composite material as defined above is provided for producing an antimicrobially active product.
  • zinc molybdate is preferably in the form of particles with an average grain size between 0.10 and 5.0 miti, more preferably in the range from 0.15 pm to less than 1.0 miti, more preferably 0.20 miti to less than 1.0 miti and even more preferably 0.25 pm to less than 1 pm and provided with at least one further material.
  • Triclinic zinc molybdate can be prepared by ultrasonically assisted reaction of one or more water-soluble molybdates with one or more water-soluble zinc (II) salts.
  • aqueous solutions of molybdate and zinc salt are provided separately and brought into contact under the influence of ultrasound.
  • the presence of ultrasound causes zinc molybdate to crystallize out in a triclinic crystal structure.
  • the particle size of the zinc molybdate can be adjusted by the duration and intensity of the ultrasound.
  • triclinic zinc molybdate is prepared by contacting an aqueous solution of one or more alkali or alkaline earth molybdates with an aqueous solution of one or more zinc (II) salts.
  • water-soluble zinc molybdate for example Sodium molybdate dihydrate can be used.
  • a zinc halide such as zinc chloride can be used as the zinc (II) salt.
  • the two salt solutions are preferably reacted at room temperature in the presence of ultrasound at a frequency of more than 15 kHz, in particular 20-30 kHz.
  • zinc molybdate must be present in a crystal lattice that is as error-free as possible. This is ensured by ultrasound treatment.
  • a mixture of the reactants such as water-soluble molybdates with one or more water-soluble zinc salts without the addition of energy does not lead to the formation of an optimal crystal structure, which is expressed by a lack or reduced effectiveness compared to the optimal crystal structure according to the invention.
  • triclinic ZnMn0 4 by means of ultrasound also enables, in particular, the defined provision of particles in the submicron range, ie greater than 0.1 pm and less than 1 pm in the sense of the invention.
  • the triclinic zinc molybdate is advantageously combined with at least one hydrophilizing and / or hygroscopic agent as defined above, the hydrophilizing and / or hygroscopic agent being arranged at least in the region of the surface of the composite material. It has proven to be particularly advantageous to coat and / or agglomerate zinc molybdate at least partially with the hydrophilizing and / or hygroscopic agent, in particular SiO 2 .
  • Triclinic zinc molybdate is clearly superior to other crystal forms and shows that the examined sample is completely sterile after 6 hours.
  • Fig. 2 shows the antimicrobial effectiveness of two different Si0 2 coatings on hospital tables (coating I & coating II) with 0.2 pm grain size of zinc molybdate against Staphylococcus aureus.
  • the coatings comprising zinc molybdate according to the invention show a marked reduction after 1 or 3 hours and complete sterility after 6 hours.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Agronomy & Crop Science (AREA)
  • Zoology (AREA)
  • Pest Control & Pesticides (AREA)
  • Toxicology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation d'une forme triclinique du molybdate de zinc (Zn Mo O4) comme agent antimicrobien, des matériaux composites qui comprennent ce molybdate de zinc et des procédés pour leur production.
EP19790230.7A 2018-10-26 2019-10-25 Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien Pending EP3869965A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18202862.1A EP3643177A1 (fr) 2018-10-26 2018-10-26 Molybdate de zinc à structure cristalline triclinique en tant que substance active antimicrobienne
PCT/EP2019/079301 WO2020084155A1 (fr) 2018-10-26 2019-10-25 Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien

Publications (1)

Publication Number Publication Date
EP3869965A1 true EP3869965A1 (fr) 2021-09-01

Family

ID=64051410

Family Applications (2)

Application Number Title Priority Date Filing Date
EP18202862.1A Withdrawn EP3643177A1 (fr) 2018-10-26 2018-10-26 Molybdate de zinc à structure cristalline triclinique en tant que substance active antimicrobienne
EP19790230.7A Pending EP3869965A1 (fr) 2018-10-26 2019-10-25 Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP18202862.1A Withdrawn EP3643177A1 (fr) 2018-10-26 2018-10-26 Molybdate de zinc à structure cristalline triclinique en tant que substance active antimicrobienne

Country Status (10)

Country Link
US (1) US20220007649A1 (fr)
EP (2) EP3643177A1 (fr)
JP (2) JP2022509569A (fr)
KR (1) KR20210110795A (fr)
CN (1) CN113316390A (fr)
BR (1) BR112021013631A2 (fr)
CA (1) CA3158369A1 (fr)
DE (1) DE202019005334U1 (fr)
SG (1) SG11202106767TA (fr)
WO (1) WO2020084155A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230042481A (ko) * 2020-07-20 2023-03-28 프리다 그룹 에이피에스 폴리옥소메탈레이트 및 아연 몰리브데이트를 포함하는 항바이러스 표면
JP2023112353A (ja) * 2022-02-01 2023-08-14 株式会社アドマテックス 複合酸化物粒子材料及びその製造方法、フィラー、フィラー含有スラリー組成物、並びにフィラー含有樹脂組成物
EP4279550A1 (fr) * 2022-05-19 2023-11-22 Speira GmbH Bande en aluminium pourvue de revêtement antibactérien
DE102022128461A1 (de) 2022-10-27 2024-05-02 Carl Freudenberg Kg Polyurethanschaum mit antimikrobieller Wirkung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040109853A1 (en) * 2002-09-09 2004-06-10 Reactive Surfaces, Ltd. Biological active coating components, coatings, and coated surfaces
CN101891252B (zh) * 2010-08-12 2012-05-23 河北联合大学 一种采用熔盐法制备钼酸锌超细抗菌粉体的方法
EP2713747B1 (fr) * 2011-05-24 2023-02-22 Agienic, Inc. Compositions et procédés pour nanoparticules métalliques antimicrobiennes
DE102013114573B4 (de) * 2013-12-19 2022-10-13 Fritz Egger Gmbh & Co. Og Verfahren zum Herstellen eines antimikrobiell wirksamen Möbel- und/oder Innenausbauteils
CN104671284B (zh) * 2014-12-29 2016-11-09 华北理工大学 超声波化学沉淀法制备超细ZnMoO4抗菌粉体
DE102015111582A1 (de) * 2015-07-16 2017-01-19 Bsn Medical Gmbh Verpackung für ein medizinisches Produkt

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EDUOK UBONG ET AL: "Ultrasound-assisted synthesis of zinc molybdate nanocrystals and molybdate-doped epoxy/PDMS nanocomposite coatings for Mg alloy protection", ULTRASONICS SONOCHEMISTRY, BUTTERWORTH-HEINEMANN, GB, vol. 44, 23 February 2018 (2018-02-23), pages 288 - 298, XP085382778, ISSN: 1350-4177, DOI: 10.1016/J.ULTSONCH.2018.02.036 *
KAREKAR S.E. ET AL: "Synthesis of zinc molybdate and zinc phosphomolybdate nanopigments by an ultrasound assisted route: Advantage over conventional method", CHEMICAL ENGINEERING AND PROCESSING: PROCESS INTENSIFICATION, vol. 87, 1 January 2015 (2015-01-01), CH, pages 51 - 59, XP093222647, ISSN: 0255-2701, DOI: 10.1016/j.cep.2014.11.010 *
See also references of WO2020084155A1 *

Also Published As

Publication number Publication date
CA3158369A1 (fr) 2020-04-30
WO2020084155A1 (fr) 2020-04-30
BR112021013631A2 (pt) 2021-11-09
DE202019005334U1 (de) 2020-04-17
JP2022509569A (ja) 2022-01-20
JP2025032171A (ja) 2025-03-11
WO2020084155A9 (fr) 2021-07-29
KR20210110795A (ko) 2021-09-09
SG11202106767TA (en) 2021-07-29
US20220007649A1 (en) 2022-01-13
CN113316390A (zh) 2021-08-27
EP3643177A1 (fr) 2020-04-29

Similar Documents

Publication Publication Date Title
EP3869965A1 (fr) Molybdate de zinc à structure cristalline triclinique utilisé comme agent antimicrobien
EP2515660B1 (fr) Formulations avec des nanoparticules d'argent
EP2988794B1 (fr) Procédé de production d'un oxyde mixte dopé pour un matériau composite et matériau composite comprenant ledit oxyde mixte
EP2140958B1 (fr) Procédé de fabrication de dispersions de nanoparticules de métal
DE102012103064A1 (de) Verbundmaterial mit einem Trägermaterial und einem antimikrobiell wirksamen Agens
EP1986500A2 (fr) Composition biocide
EP2654429B1 (fr) Procede de preparation d'une dispersion contenant des nanoparticules d'argent et utilisation comme revetement d'une composition contenant des nanoparticules d'argent
DE202014011236U1 (de) Antimikrobiell wirksamer Verbundwerkstoff
DE19935230C2 (de) Biofilmhemmendes Mittel
DE69126520T2 (de) Antimikrobielle Zusammensetzung mit einer Hitze- und Witterungsbeständigkeit
EP2813247A1 (fr) Polymère équipé d'antimicrobien avec particules intégrées et élément de désinfection à base de ce polymère
EP3881679A1 (fr) Matières composites antimicrobiennes améliorées contenant du tungstène
EP4181678A2 (fr) Surfaces à effet antiviral contenant des polyoxométallates et du molybdate de zinc
DE102007008026A1 (de) Biozide Zusammensetzung
DE102004057628A1 (de) Mikroben inaktivierende Elastomere
DE102021107923A1 (de) Beschichtung gegen Algen- und Pilzbefall
Quintero-González et al. Aggregation Study of Ag-TiO 2 Composites

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20210521

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20241120

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载